Shuangli Zhu,Kai Fu,Sijia Li et al.
Shuangli Zhu et al.
Cancer is one of the leading causes of death worldwide. Recent advances in precision oncology have enabled many specific cancer patient populations to respond well and achieve longer survival with small-molecule kinase inhibitors, which hav...
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer [0.03%]
供体细胞治疗引起的移植物抗宿主病及其对策
Zibai Lyu,Siyue Niu,Ying Fang et al.
Zibai Lyu et al.
Allogeneic cell-based immunotherapies, particularly CAR-T cell therapy, represent a significant advancement in cancer treatment, offering scalable and consistent alternatives to autologous therapies. However, their widespread use is limited...
IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway [0.03%]
CD109通过稳定白细胞介素-6受体-α和激活STAT3/NRF2途径驱动鳞状细胞癌的IL-6介导的肿瘤发生性和抗氧化状态
Amani Hassan,Tenzin Kungyal,Shufeng Zhou et al.
Amani Hassan et al.
Background: Squamous cell carcinoma (SCC) is a prevalent malignancy and there are limited options to block the recurrence and metastasis that often occur in SCC patients. Although IL-6, a proinflammatory cytokine, is stro...
Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential [0.03%]
免疫检查点在肝细胞癌治疗中的作用：具有潜在治愈效果的联合策略的研究
Jing Tong,Yongci Tan,Wenwen Ouyang et al.
Jing Tong et al.
Hepatocellular carcinoma (HCC) is a primary liver cancer characterized by poor immune cell infiltration and a strongly immunosuppressive microenvironment. Traditional treatments have often yielded unsatisfactory outcomes due to the insidiou...
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival [0.03%]
CAR-T治疗的淋巴瘤患者的低镁血症与免疫功能障碍和生存率下降相关
Jennifer J Gile,Patrizia Mondello,Zixing Wang et al.
Jennifer J Gile et al.
Background: Hypomagnesemia has been correlated with inferior outcomes in patients with large B cell lymphoma (LBCL) undergoing stem cell transplants. As T-cell and myeloid cell dysfunction have been associated with low ma...
Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma [0.03%]
肝细胞癌的成像和靶向给药用工程纳米粒子
Xianzhe Yu,Qin Zhang,Leibo Wang et al.
Xianzhe Yu et al.
Liver cancer, notably hepatocellular carcinoma (HCC), poses a significant global health burden due to its high fatality rates. Conventional antitumor medications face challenges, including poor targeting, high toxicity, and drug resistance,...
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study [0.03%]
低甲基化药物联合维奈克拉作为高危MDS和CMML移植前的桥接治疗：GESMD研究
Ines Zugasti,Monica Lopez-Guerra,Sandra Castaño-Díez et al.
Ines Zugasti et al.
Background: High-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML) remain therapeutic challenges with suboptimal outcomes. The only potentially curative treatment is allogeneic stem cell t...
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export [0.03%]
甜菜碱通过PDK4/PDHA1信号和NMDAR介导的铁输出双重激活铁死亡从而增强非小细胞肺癌化疗敏感性
Guangyao Shan,Yunyi Bian,Shencheng Ren et al.
Guangyao Shan et al.
Background: Ferroptosis, a regulated cell death driven by iron-dependent lipid peroxidation, is associated with chemoresistance in lung adenocarcinoma (LUAD). This study aims to investigate the role of sarcosine in ferrop...
Anti-angiogenic tyrosine kinase inhibitors and the pathophysiology of their toxic effects: revisiting the treatment of anemia in metastatic cancers [0.03%]
血管生成抑制酪氨酸激酶抑制剂及其毒性作用的病理生理学：重新审视转移性癌症贫血治疗
Tai Van Nguyen,Eurydice Angeli,Diaddin Hamdan et al.
Tai Van Nguyen et al.
Background: Anti-angiogenic tyrosine kinase inhibitors (TKIs) have become major drugs for the treatment of various cancer types, but with an overall high incidence of severe toxicities, particularly haematological toxicit...
Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024 [0.03%]
CAR-T细胞疗法在急性髓系白血病中的突破进展：来自2024年ASH会议的更新
Haixiao Zhang,Hong-Hu Zhu
Haixiao Zhang
While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for lymphoid malignancies, its greatest challenge remains in the treatment of acute myeloid leukemia (AML). Its success in AML has been limited ...